From CNBC:

Two gene therapies have been approved to treat sickle cell disease, offering hope to patients. However, the costly treatments pose accessibility challenges. Patient Michael Goodwin, who battles unpredictable pain, worries about intensive medical preparation and hefty price tags. Despite the breakthrough, equitable access and infrastructure issues linger, leaving some hesitant.



Read more: Sickle cell disease gene therapies Casgevy Lyfgenia insurance cost issues